Clinical Trial Update: Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating trametinib in combination with docetaxel for KRAS-mutant non-small cell lung cancer; results have been posted and the study is currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• MEKINIST (trametinib)
• Taxotere (docetaxel)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: KRAS Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-02-02